Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?
AACR Annual Meeting 2021
Charlotte E. Ariyan, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses improved outcomes with metastasectomy in the setting of checkpoint inhibitors, with the removal of residual disease and “escape” lesions. Surgical outcomes may also be better than targeted treatments, although long-term data and biomarkers are needed to confirm these findings.
The ASCO Post Staff
Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements (Abstract CT010).
The ASCO Post Staff
Jessica C. Hassel, MD, of University Hospital Heidelberg, discusses phase III results of a study that compared tebentafusp, a bispecific fusion protein, with investigator’s choice in patients with metastatic uveal melanoma. Tebentafusp nearly halved the risk of death among patients in the trial with this rare eye cancer (Abstract CT002).
The ASCO Post Staff
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.
The ASCO Post Staff
Jeanne Tie, MD, MBChB, of the Peter MacCallum Cancer Centre, discusses how to improve the current, somewhat imprecise, approach based on pathologic staging alone, used to select patients for adjuvant treatment. Circulating tumor DNA analysis after curative-intent treatment may detect minimal residual disease and might be used to predict recurrence and adjuvant treatment efficacy across multiple tumor types.
The ASCO Post Staff
Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the challenges in developing CAR T-cell therapy, as well as the progress being made, such as creating hybrid CAR and T-cell receptors that should enable T cells to recognize much lower levels of antigens. The field, he says, is poised to take on a range of solid tumors to extend the successes in hematologic malignancies.
